Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 2Leukemia 2Triple Negative Breast Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Neoplasm Metastasis 1Leukemia, Lymphocytic, Chronic, B-Cell 1Influenza, Human 1Hematologic Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 43Nivolumab 24Gemcitabine 23Cyclophosphamide 21Paclitaxel 17Capecitabine 16fludarabine 14Ipilimumab 14aldesleukin 11Docetaxel 11130-nm albumin-bound paclitaxel 11Trastuzumab 10Cetuximab 10Bevacizumab 10Albumin-Bound Paclitaxel 9fludarabine phosphate 8Specimen Handling 8Interleukin-2 8Fluorouracil 8Cisplatin 8Biopsy 8Radiosurgery 7Oxaliplatin 7Irinotecan 7durvalumab 6avelumab 6Temozolomide 6Pemetrexed 6Leucovorin 6Carboplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm Metastasis × Interferon alpha-2 × Clear all
NCT01545141 2023-10-27

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Roswell Park Cancer Institute

Phase 1/2 Terminated
15 enrolled 9 charts
Gastrointestinal

Neoplasm Metastasis, Recurrence, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡